Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 2512536, 9 pages
https://doi.org/10.1155/2017/2512536
Research Article

Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL

1Department of Urology, The People’s Hospital of Wujiang City, Suzhou, Jiangsu, China
2Department of Urology, Shanghai Shibei Hospital of Jingan District, Shanghai, China
3Department of Anesthesiology, The Third People’s Hospital of Yancheng, Yancheng, Jiangsu, China

Correspondence should be addressed to Minjun Jiang

Received 19 May 2016; Revised 20 August 2016; Accepted 31 October 2016; Published 15 February 2017

Academic Editor: Tarek A. Bismar

Copyright © 2017 Yongqiang Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Cuzick, M. A. Thorat, G. Andriole et al., “Prevention and early detection of prostate cancer,” The Lancet Oncology, vol. 15, no. 11, pp. e484–e492, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. M. J. Barry, “Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer,” The New England Journal of Medicine, vol. 344, no. 18, pp. 1373–1377, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Stephan, B. Ralla, and K. Jung, “Prostate-specific antigen and other serum and urine markers in prostate cancer,” Biochimica et Biophysica Acta—Reviews on Cancer, vol. 1846, no. 1, pp. 99–112, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Ochiai, K. Okihara, K. Kamoi et al., “Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy,” BJU International, vol. 111, no. 6, pp. 928–933, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. F. B. Wang, R. Chen, S. C. Ren et al., “Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy,” Asian Journal of Andrology, vol. 19, no. 2, pp. 238–243, 2017. View at Google Scholar
  6. F. Wang, S. Ren, R. Chen et al., “Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer,” Oncotarget, vol. 5, no. 22, pp. 11091–11102, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Weng, J. Wang, Y. Cai et al., “Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers,” International Journal of Cancer, vol. 113, no. 5, pp. 811–818, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Rigau, J. Morote, M. C. Mir et al., “PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine,” The Prostate, vol. 70, no. 16, pp. 1760–1767, 2010. View at Google Scholar · View at Scopus
  9. V. N. Talesa, C. Antognelli, C. Del Buono et al., “Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers,” Cancer Biomarkers, vol. 5, no. 6, pp. 241–251, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. F. Berger, M. S. Lawrence, F. Demichelis et al., “The genomic complexity of primary human prostate cancer,” Nature, vol. 470, no. 7333, pp. 214–220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. G. H. J. M. Leyten, D. Hessels, F. P. Smit et al., “Identification of a candidate gene panel for the early diagnosis of prostate cancer,” Clinical Cancer Research, vol. 21, no. 13, pp. 3061–3070, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. K. P. Nickens, A. Ali, T. Scoggin et al., “Prostate cancer marker panel with single cell sensitivity in urine,” The Prostate, vol. 75, no. 9, pp. 969–975, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Ren, Z. Peng, J.-H. Mao et al., “RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings,” Cell Research, vol. 22, no. 5, pp. 806–821, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Magi-Galluzzi, T. Tsusuki, P. Elson et al., “TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients,” The Prostate, vol. 71, no. 5, pp. 489–497, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Lee, J. Y. Chae, C. Kwak, J. H. Ku, and K. C. Moon, “TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients,” Urology, vol. 76, no. 5, pp. 1268.e7–1268.e13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Laxman, D. S. Morris, J. Yu et al., “A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer,” Cancer Research, vol. 68, no. 3, pp. 645–649, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. A. J. Vickers and E. B. Elkin, “Decision curve analysis: a novel method for evaluating prediction models,” Medical Decision Making, vol. 26, no. 6, pp. 565–574, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. J. S. Ross, C. E. Sheehan, H. A. G. Fisher et al., “Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer,” Clinical Cancer Research, vol. 9, no. 17, pp. 6357–6362, 2003. View at Google Scholar · View at Scopus
  19. Z. Xiao, B.-L. Adam, L. H. Cazares et al., “Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease,” Cancer Research, vol. 61, no. 16, pp. 6029–6033, 2001. View at Google Scholar · View at Scopus
  20. M. Rigau, I. Ortega, M. C. Mir et al., “A three-gene panel on urine increases PSA specificity in the detection of prostate cancer,” The Prostate, vol. 71, no. 16, pp. 1736–1745, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Yang, R. C. Mease, M. Pullambhatla et al., “[18F]Fluorobenzoyllysinepentanedioic Acid Carbamates: new scaffolds for Positron Emission Tomography (PET) imaging of Prostate-Specific Membrane Antigen (PSMA),” Journal of Medicinal Chemistry, vol. 59, no. 1, pp. 206–218, 2015. View at Publisher · View at Google Scholar
  22. W. Fan, Z. Zhang, Z. Zhu et al., “Synthesis and positron emission tomography evaluation of F-Glu-Urea-Lys, a prostate-specific membrane antigen-based imaging agent for prostate cancer,” Oncology letters, vol. 10, pp. 2299–2302, 2015. View at Google Scholar
  23. U. Haberkorn, M. Eder, K. Kopka, J. W. Babich, and M. Eisenhut, “New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy,” Clinical Cancer Research, vol. 22, no. 1, pp. 9–15, 2016. View at Publisher · View at Google Scholar · View at Scopus